Recent clinical trials clarified that combined MEK (trametinib) and BRAF (dabrafenib) inhibition is effective molecular-targeted therapy for melanoma patients harbouring BRAF mutation, suggesting that the RSK–EphA2 pathway inhibition affects the therapeutic efficacy52. The gene discussed is EPHA2; the disease is melanoma.